$INDV: Indivior Reports Q3 2026: Revenue Up 13% to $356M, Diluted EPS Surges

$INDV

$INDV – Indivior Reports Q3 2026: Revenue Up 13% to $356M, Diluted EPS Surges to $1.12

Indivior Pharmaceuticals, Inc.

2026-10-29 00:00:00 UTC · SEC_8K · All $INDV

?? Positive AI Sentiment (+7.5 / 10)

Q3 Total Net Revenue rose 13% YoY to $356M, led by SUBLOCADE up 22% to $267M.
Diluted EPS reached $1.12 vs $0.33 in prior-year quarter; Net Income expanded to $137M.
Adjusted EBITDA surged 76% YoY to $211M with margins expanding 2,100 bps to 59%.